The Technical Analyst
Oncternal Therapeutics [ONCT]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Oncternal Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals
3.02% $8.86
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 26.22 mill |
| EPS: | -13.43 |
| P/E: | -0.660 |
| Earnings Date: | May 01, 2024 |
| SharesOutstanding: | 2.96 mill |
| Avg Daily Volume: | 0.0098 mill |
| RATING 2024-04-19 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.660 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.11x |
| Company: PE -0.660 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.487 (-94.50%) $-8.37 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 8.26 - 9.46 ( +/- 6.79%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-08 | Wills Robert James | Buy | 3 086 | Common Stock |
| 2024-03-28 | Wills Robert James | Buy | 6 914 | Common Stock |
| 2024-02-23 | Hale David F | Buy | 266 | Common Stock |
| 2024-02-23 | Hale David F | Buy | 714 | Common Stock |
| 2024-02-23 | Wills Robert James | Sell | 980 | Common Stock |
| INSIDER POWER |
|---|
| 19.18 |
| Last 100 transactions |
| Buy: 5 802 851 | Sell: 3 918 128 |
Forecast:
16:00 - $8.86
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $8.86
Forecast 2: 16:00 - $8.86
Forecast 3: 16:00 - $8.86
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $8.86 (3.02% ) |
| Volume | 0.0044 mill |
| Avg. Vol. | 0.0098 mill |
| % of Avg. Vol | 45.26 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ONCT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ONCT
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.
Latest Press Releases
2024-04-18 09:00:00 - Press Release
Oncternal Announces First Patient Dosed In Fourth Cohort Of Phase 1/2 Study Of Onct-534 For The Treatment Of R/r Metastatic Castration-resistant Prostate Cancer
San diego, april 18, 2024 (globe newswire) -- oncternal therapeutics, inc. (nasdaq: onct), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the fourth cohort of its phase 1/2 study of onct-534 for the treatment of patients with advanced prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (arpi). patients in the fourth dosing cohort will receive onct-534, the company's dual-action androgen receptor inhibitor (daari), at a dose of 300 mg taken orally each day. the decision to proceed to this higher dose level was made by the study's safety review committee (src) after reviewing data from the patients treated to date, including the third dose level of 160 mg onct-534 daily.
2024-03-15 09:00:00 - Press Release
Oncternal Participating In Virtual Fireside Chat With Key Opinion Leader On Treatment Landscape & New Treatment Options For Prostate Cancer
San diego, march 15, 2024 (globe newswire) -- oncternal therapeutics, inc. (nasdaq: onct), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced it will participate in a virtual fireside chat on the treatment landscape & new treatment options for prostate cancer.
2024-03-07 16:01:00 - Press Release
Oncternal Therapeutics Provides Business Update And Announces Fourth Quarter And Full Year 2023 Financial Results
San diego, march 07, 2024 (globe newswire) -- oncternal therapeutics, inc. (nasdaq: onct), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported fourth quarter and full year 2023 financial results.
2024-02-29 16:05:00 - Press Release
Oncternal Therapeutics To Provide Business Update And Report Fourth Quarter And Full Year 2023 Financial Results
San diego, feb. 29, 2024 (globe newswire) -- oncternal therapeutics, inc. (nasdaq: onct), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report fourth quarter and full year 2023 financial results after the u.s. financial markets close on thursday, march 7, 2024. oncternal's management will host a webcast at 2:00 p.m. pt (5:00 p.m. et) to provide a business update and discuss the company's financial results.
2024-02-06 16:30:00 - Press Release
Oncternal Therapeutics To Participate In Oppenheimer 34th Annual Healthcare Life Sciences Conference
San diego, feb. 06, 2024 (globe newswire) -- oncternal therapeutics, inc. (nasdaq: onct), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that james breitmeyer, m.d, ph.d., oncternal's president and chief executive officer will participate in a fireside chat at the oppenheimer 34th annual healthcare life sciences conference, to be held virtually february 13-14, 2024.
Latest News
2024-03-07 20:46:07 - Seeking Alpha
Oncternal Therapeutics, Inc. (ONCT) Q4 2023 Earnings Call Transcript
Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q4 2023 Results Conference Call March 7, 2024 5:00 PM ET Company Participants Richard Vincent - CFO Dr. James Breitmeyer - President and CEO Dr. Salim Yazji - Chief Medical Officer Conference Call Participants Carl Byrnes - Northland Capital Markets Hartaj Singh - Oppenheimer Kemp Dolliver - Brookline Capital Markets Operator Greetings, and welcome to Oncternal's Fourth Quarter 2023 Financial Results Call. At this time, all participants are in a listen-only mode.
2024-03-07 18:36:03 - Zacks Investment Research
Oncternal Therapeutics (ONCT) Reports Q4 Loss, Tops Revenue Estimates
Oncternal Therapeutics (ONCT) came out with a quarterly loss of $3.11 per share versus the Zacks Consensus Estimate of a loss of $3.09. This compares to loss of $4 per share a year ago.
2023-11-09 21:07:09 - Seeking Alpha
Oncternal Therapeutics, Inc. (ONCT) Q3 2023 Earnings Call Transcript
Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q3 2023 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants Richard Vincent - CFO James Breitmeyer - President and CEO Salim Yazji - Chief Medical Officer Conference Call Participants Carl Byrnes - Northland Securities Hartaj Singh - Oppenheimer Kemp Dolliver - Brookline Capital Markets Operator Greetings and welcome to Oncternal Therapeutics third-quarter 2023 financial results conference call. [Operator Instructions].
2023-08-10 20:43:04 - Seeking Alpha
Oncternal Therapeutics, Inc. (ONCT) Q2 2023 Earnings Call Transcript
Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q2 2023 Earnings Conference Call August 10, 2023 5:00 PM ET Company Participants Salim Yazji - CMO James Breitmeyer - President, CEO Richard Vincent - CFO Conference Call Participants Carl Byrnes - Northland Capital Markets Hartaj Singh - Oppenheimer & Company Rosemary Li - Cantor Fitzgerald Kemp Dolliver - Brookline Capital Markets Operator Greetings and welcome to the Oncternal Second Quarter 2023 Financial Results Call. At this time, all participants are in a listen-only mode.
2023-08-10 19:01:45 - Zacks Investment Research
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Lags Revenue Estimates
Oncternal Therapeutics (ONCT) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.23 per share a year ago.
2023-05-04 22:53:04 - Seeking Alpha
Oncternal Therapeutics, Inc. (ONCT) Q1 2023 Earnings Call Transcript
Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q1 2023 Results Conference Call May 4, 2023 5:00 PM ET Company Participants Salim Yazji - CMO James Breitmeyer - President, CEO Richard Vincent - CFO Conference Call Participants Hartaj Singh - Oppenheimer Carl Byrnes - Northland Capital Markets Rosemary Li - Cantor Fitzgerald Kemp Dolliver - Brookline Capital Markets Operator Greetings, and welcome to the Oncternal Therapeutics First Quarter 2023 Financial Results Call. [Operator Instructions] As a reminder, this conference will be recorded.
2023-05-04 19:44:48 - Zacks Investment Research
Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates
Oncternal Therapeutics (ONCT) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.20 per share a year ago.
2023-04-19 15:29:56 - PennyStocks
Penny Stocks To Buy? 10 Under $1 To Watch This Week
2023-04-17 11:15:14 - PennyStocks
Penny Stocks To Buy? 7 Under $1 To Watch This Week
2023-04-04 13:42:29 - Zacks Investment Research
Oncternal (ONCT) Down on Restructuring Plan to Extend Runway
Oncternal (ONCT) closes the development program for zilovertamab to extend its cash runway into 2025. Shares are down on the same.